Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is a question no one knows the answer to and will only lead to speculation. The word I received was that they would be on time. I trust what I heard.
The due date is the 16th. And yes they will file on time.
Continue to add. 30K shares yesterday. The .09 range. Market Makers holding it back in between news cycles on very low volume. Great add range here imo.
Lots of valuable information in today’s CEO blog including…”So, it should not be a surprise that we are talking to the National Eye Institute (NEI) at NIH about collaborating on the first clinical trials of our reformulation of metformin into an eye drop to treat age-related macular degeneration.” This would be huge, especially since one of the doctor’s on the CUBT advisory board, Dr. Kapil Bharti, is from the National Eye Institute at the NIH.
CEO reiterates goal of completing IND by the end of the year and to be in trials in Q1 2022.
Added a few more today. Exercising patience here as they execute their plan.
Moczowy did the independent directors designation show up today?
Or a screen shot? LOL
Added at .0951.
Added a few today under .10. IRobot you need evidence or are we good?
Adding a few here under .10.
Oh ye of little faith….you shall know the truth and the truth shall set you free. Learn to trust more, you will live longer and be happier, and so will those around you. I have done this many many times in accumulating over 3 million shares.
BOUGHT Connectyx Tech Hldgs (Symbol:
CUBT)
Quantity
250 2,500 250 250 250 250 250 250 100 250 250 250 250 190 9,810 250 15,600
For this security:
Price ($)
0 .105 0 .105 0 .105 0 .105 0 .105 0 .105 0 .1002 0 .105 0 .105 0 .105 0 .105 0 .105 0 .1047 0 .1005 0 .1005 0 .105
Principal ($)
26.25 262.50 26.25 26.25 26.25 26.25 25.06 26.25 10.50 26.25 26.25 26.25 26.19 19.10 985.91 26.25
$ 1,591.76
Type: Cash
Charges and/or Interest ($)
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Trade Confirmation
Trade: 07/27/21
Settle: 07/29/21
Total Amount ($)
26.25 262.50 26.25 26.25 26.25 26.25 25.06 26.25 10.50 26.25 26.25 26.25 26.19 19.10 985.91 26.25
$ 1,591.76
Added a few at .1005.
Must be close to getting IND cleared through the FDA.
Very common in cases like this to set the exercise price near current market. Three year vesting - the price will not be .12 when these vest in 1/3 increments over the next three years. From you post it seems you were implying something. What is it? Or was I misinterpreting “amazing”?
Nice try.
What companies are you talking about, what solutions do they have and how much money do they have? Curious on your DD.
Do your homework.
Totally agree. The interview was eye opening. Richard Garr knows his business. He was very impressive. And they all have been down this road before. They have the know how and the market expertise to execute.
Paul Michael’s….
Paul Richards on the appointment of Marc Drimer, CPA to their Board: “We are excited and eager to begin working with Marc in developing capital market options and potential partnerships as the Company advances its therapeutic pipeline.”
Potential partnerships is what jumped out at me. Given what CEO said about the “imminent” timing of the completion of their audit, very intrigued by the timing of announcing a CPA with his background onto their board. Good things ahead imo despite normal daily fluctuations on price.
Or we could all win if this is one of the stocks not on the list. BTW it won’t be on the list. One would know this if they actually did their homework. This is a completely fear based post with no basis of accurate information.
You can only beat a dead horse for so long. He’s going to believe what he wants to believe which is based on a foundation of distrust. Tough way to live life when you disregard facts and believe whatever you want to believe.
Yes I got an email from Steve. Nice touch.
Great interview. Richard is a smart guy, a walking encyclopedia in their areas. His level of technical knowledge was impressive, particularly for a trained lawyer. Knows his stuff. Even more excited about their future after listening to Richard talk about the company and opportunities for an hour. This all star cast will produce in my opinion.
Pretty obvious that many people would rather just complain instead of picking up the phone and calling the IR person and asking him how they are using the money. They are using it to fund their business and the three solutions they have in process.
When someone makes comments about spending the money on blow and hookers it’s hard to take that seriously. As for the $600K, call the IR guy and ask. It’s not that difficult.
My understanding is that the investor was a repeat investor who believes in what the company is doing. Unlikely he sold. But again who knows? I just choose to believe it was a repeat investor and not over think it. But that is just me.
The truth is you have no idea what other owners do. Speculate all you want. But you have no clue.
Why don’t you call the IR guy and find out. It’s really not that difficult.
Agree completely. Still early innings. I’ll be patient. Love the Metformin potential. Need to see it through. Animal trials going on now.
They will do a PR on financing when it’s done.
The action to me seems like it is market makers trying to keep the price down. Just my observation based on orders I have been putting in and corresponding price action. I bought today and price immediately went down. I will wait patiently.
And I’ll be buying. Until there is volume/liquidity from material news, price does not matter. And if there is some news who’s selling?
You’re smooth man. I see what you did there.
Exactly. It’s the Dr. Jekyll and Mr. Hyde board. Pretty humorous. And what has really changed, other than a filing about an investor who bought 10M shares at .06.
Seen this same pattern so many times with OTC plays. Still not convinced much could have been done short of a significant material event that would have slowed the decline. Many low volume days when market makers slow walked it on down in between news cycles. Flippers gonna flip. Others will hold. If you believe where they are going hold it, buy the dips, if you don’t sell it. Pretty clear at this point CUBT management is not going to bend to desires of investors, whether one likes or agrees with it or not. One day they will drop a material PR and this recent decline will be in the rear view mirror.
Quote from 18 days ago June 4th:
“I'm back on the cho cho train lol!. And I can absolutely promise you I have not bought any shares the past 2 days other than 170 K the other day at .082. And when you have over 5 M that really makes no difference.
However I do think 4 things have turned me around.
They actually hired an IR person. Great step.
Ox's post.
Chart and buying says support at .08...as it should.
Finally I emailed my contact out of NYC this afternoon and he responded with one phrase....Bombs incoming.
I can only take that as a good thing.
As to the other post about the financing and the news after the N and S change. I for sure was not the only one 'given' that impression, but I was very outspoken about that. I own up to that.
Only thing I can say is I hope something came along (deals) that delayed that.”
Do recent posts mean you are now off the choo choo train that you got back onto 18 days ago? You get on and off the train frequently.
People need to stop throwing darts at boards. This will move when there is material news. Period. Market makers will pull it back and some people will sell. I added today.
I believe any cash on hand is to keep thing moving forward, paying the bills etc. Don’t think they have any cash for a material stock buy back. Stock buy back will not happen here.
For sure. How can that possibly happen when their goal is to get the IND submitted by the end of the year for Metformin which is the primary focus and best short term solution.